SEC Comment Letter 0000000000-25-000888 to Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070) (NEUP)
Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070)
Date: Jan. 28, 2025 · CIK: 0001191070 · Accession: 0000000000-25-000888
AI Filing Summary & Sentiment
File numbers found in text: 333-284512
Letter
January 28, 2025 Spyros Papapetropoulos, M.D. Chief Executive Officer Neuphoria Therapeutics Inc. 100 Summit Dr. Burlington, Massachusetts 01803 Re:Neuphoria Therapeutics Inc. Registration Statement on Form S-3 Filed January 24, 2025 File No. 333-284512 Dear Spyros Papapetropoulos M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Theodore Ghorra
Show Raw Text
January 28, 2025
Spyros Papapetropoulos, M.D.
Chief Executive Officer
Neuphoria Therapeutics Inc.
100 Summit Dr.
Burlington, Massachusetts 01803
Re:Neuphoria Therapeutics Inc.
Registration Statement on Form S-3
Filed January 24, 2025
File No. 333-284512
Dear Spyros Papapetropoulos M.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Theodore Ghorra